Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis

Novikov P.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Kuznetsova E.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow

Nosova N.: Sechenov First Moscow State Medical University

Shevtsova T.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Litvinova M.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University

Logina V.: Faculty of Medicine, Lomonosov Moscow State University, Moscow, Russia

Moiseev S.: Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia

Download in PDF

Summary

Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.

Key words

Levilimab, IL-6 receptor inhibitor, rheumatoid arthritis, treatment.